Your Shopping Cart
By using this site you agree to our use of cookies. Please refer to our privacy policy for more information. Close
Hello. Sign In
Your Account

Log In to ComplianceOnline
Welcome back! Please log in below to continue.
0
Cart
Toll Free:
+1-888-717-2436
+1-888-717-2436
Industries
- Banking & Financial Services
- BANKING & FINANCIAL SERVICES
- Banks and Credit Unions
- Financial Services and Trading
- Insurance
- Accounting and Taxation
- Life Sciences
- Hitech, Aero & Manufacturing
- HITECH, AERO & MANUFACTURING
- Quality & Safety
- Standards and Methodology
- Energy & Utilities
- ENERGY & UTILITIES
- IT Security
- Reliability (NERC / FERC)
- Quality and Safety
- Risk Management
- CPG & Retail
- CPG & RETAIL
- Retail Audit
- Quality & Safety
- Social Compliance
- Healthcare
- Food & Dietary Supplements
- Cross Industry Functions
Webinars
By Industries
Seminars
The Drug Development Process from Concept to Market
Analytical Instrument Qualification and System Validation
Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)
HIPAA Privacy Rule Compliance-Understanding New Rules and Responsibilities of Privacy Officer
Biocompatibility Testing: What You Need to Know
Navigating the Medical Device Post-Market Maze and Challenges ...
Coping with FDA Import Delays, including COVID-19, Expedited Imports and Detentions
The Veterinary Drug Approval Process and FDA Regulatory Oversight
Regulatory Compliance for Dietary Supplements in the US, EU and Canada
Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions
Standards
Aerospace
Agriculture and Farm Machinery
Automotive, Aircraft & Marine technology
Banking, Corp. finance & Sox
Biotech & Pharmaceutical Standards
Chemical technology
Civil engineering and construction
Computer Hardware
Electrical Engineering
Electronic Equipment
ANSI
Audit Net
BIN
BPA
Business Basics
Complianceonline
IT Governance
LabCompliance
Quality-Control-Plan
RCGLOBAL
SHOQ Quality Assurance Manuals
SEPT
Home
› Best Practices
FDA Guidance on Assessment of Drugs Abuse Potential
- By: Staff Editor
- Date: February 21, 2017
- Source: https://www.fda.gov
FDA Guidance on Assessment of Drugs Abuse Potential
The abuse potential of a drug is a vital consideration in the development of a new drug. Physicians and healthcare providers need to know if the new drug is expected to be abused after approval and marketing to assure the protection of public health. Assessing drug abuse potential also provides the basis for controlling and regulatory actions related to drug control.
As a component of the safety evaluation of the new drug, FDA has recently finalized the guidance to aid investigational drug sponsors in assessing whether their new drug has abuse potential. According to this guidance, if the drug substance is CNS active and produce adverse effects such as hallucinations, the drug is likely to undergo detailed assessment of its abuse potential and is subjected to control under the Controlled Substances Act (CSA).
Related Training:
Overview of the Requirements
The guidance covers drug products that contain CNS-active new molecular entities (NMEs) along with those products that contain CNS-active substances that are already regulated under the CSA. The key areas addressed in this guidance include:
- Chief decision points in assessing abuse potential including answers to the following questions:
- Is the new drug active within the CNS?
- What is the next step for evaluating abuse potential for CNS-active new drugs?
- Should a human abuse potential study be conducted?
- Preparing the NDA submission.
- NDA review and product labeling related to abuse potential.
- Abuse-related data from chemistry and nonclinical studies including pharmacological studies, pharmacokinetic data, and general animal behavioral effects.
- Abuse-related data from clinical studies including abuse-related adverse events from human studies, human abuse potential studies, clinical studies that evaluate cognition and performance, and clinical evaluation of physical dependence studies.
The guidance also offer recommendations on the use of post-marketing and illicit drug abuse data to ensure adherence to the FDA regulatory requirements.

Compliance Trainings

Pregnancy in the Workplace: Strategies to Protect Your Organization from Pregnancy Discrimination Claims
By - Christopher W. Olmsted
On Demand Access Anytime
By - Christopher W. Olmsted
On Demand Access Anytime

How to Vet an IRB: Expose and Fix Problems Before They Threaten Your Trial
By - Madhavi Diwanji
On Demand Access Anytime
By - Madhavi Diwanji
On Demand Access Anytime

Compliance Standards
Best Sellers
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
By: Miles HutchinsonAdd to CartPrice: $249
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
San Francisco, CA | Aug 6-7, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 18-19, 2020
-
Los Angeles, CA | Aug 20-21, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 25-26, 2020
-
Virtual Seminar | Jun 10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | Jul 6-7, 2020
-
San Francisco, CA | Oct 22-23, 2020
-
Virtual Seminar | Jul 9-10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | June 3-4, 2020
-
Miami, FL | Jul 29-31, 2020
-
Virtual Seminar | Jun 17, 2020
-
Provider: ANSIAdd to CartPrice: $142
- Add to Cart
- Add to Cart
- Add to Cart
-
Provider: ANSIAdd to CartPrice: $120
-
Provider: ANSIAdd to CartPrice: $250
-
Provider: SEPTAdd to CartPrice: $299
- Add to Cart
-
Provider: Quality-Control-PlanAdd to CartPrice: $37
- Add to Cart
-
Provider: At-PQCAdd to CartPrice: $397
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
You Recently Viewed
